C4 Therapeutics (CCCC) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($408.4 million vs $346.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | EIKN |
|---|---|---|
| Share price | $2.82 | $7.54 |
| Market cap | $346.93M | $408.40M |
| 1-day change | -2.08% | +0.40% |
| YTD return | +47.64% | — |
| 1-year return | +24.78% | — |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-0.91 | $-8.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $17.40 |
| 52-week low | $1.69 | $7.02 |
| Distance from 52-week high | -45.45% | -56.67% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +372.70% | +226.26% |
| Average volume | 2.38M | 492.68K |
| Shares outstanding | 123.03M | 54.17M |
| Employees | 104 | 384 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
CCCC vs EIKN FAQ
Which is bigger, C4 Therapeutics or Eikon Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $408.40M compared with $346.93M for C4 Therapeutics (CCCC).
Are C4 Therapeutics and Eikon Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.